



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/615158	
			Filing Date	July 7, 2003	
			First Named Inventor	Gilbard, Jeffrey P.	
			Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	AVR-005

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
Z.F	A1	Akbar, M. <i>et al.</i> "Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway." <i>Journal of Neurochemistry</i> 82:655-665 (2002).		
	A2	Caughey, G.E. <i>et al.</i> "The effect on human tumor necrosis factor α and interleukin 1 β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil." <i>Am. J. Clin. Nutr.</i> 63:116-22 (1996).		
	A3	Curtis, C.L. <i>et al.</i> "n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation." <i>The Journal of Biological Chemistry</i> 275(2):721-724 (2000).		
	A4	Kishida, E. <i>et al.</i> "Distinctive inhibitory activity of docosahexaenoic acid against sphingosine-induced apoptosis." <i>Biochimica et Biophysica Acta</i> 1391:401-408 (1998).		
	A5	Kronemyer, B. "Dry eye successfully treated with oral flaxseed oil." <i>Ocular Surgery News EUROPE/ASIA-PACIFIC EDITION</i> retrieved from the internet at http://www.osnsupersite.com/default.asp?ID=390 2pp. (2000).		
	A6	Oxholm, P. <i>et al.</i> "Essential fatty acid status in cell membranes and plasma of patients with primary Sjögren's syndrome." <i>Prostaglandins, Lukotrienes and Essential Fatty Acids</i> 59(4):239-245 (1998).		
	A7	Sullivan, B.D. <i>et al.</i> "Correlations between nutrient intake and the polar lipid profiles of meibomian gland secretions in women with Sjögren's syndrome." in <u>Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3</u> edited by Sullivan, D. <i>et al.</i> , Kluwer Academic/Plenum Publishers pp.441-447 (2002).		
	A8	Yano, M. <i>et al.</i> "Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor." <i>J. Nutr.</i> 130(5):1095-1101 (2000).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Robert F. ...</i>	Date Considered	7/24/06
-----------------------	----------------------	--------------------	---------